Efficient amyloid-β degradation in Alzheimer's disease using SPYTACs - PubMed
2 hours ago
- #Alzheimer's disease
- #Amyloid-β degradation
- #Targeted protein degradation
- SPYTACs (synthetic peptide-programmed lysosome-targeting chimeras) offer a novel approach for targeted degradation of amyloid-β (Aβ) in Alzheimer's disease.
- SPYTACs utilize low-density lipoprotein receptor-related protein 1 (LRP1) to facilitate degradation of extracellular proteins and cross the blood-brain barrier.
- In vivo studies show SPYTACs reduce Aβ burden, prevent synapse loss, and improve cognitive function in 5×FAD mice with fewer side effects compared to traditional immunotherapies.
- The modular and genetically encodable nature of SPYTACs allows customization for targeting various disease-causing proteins, enhancing therapeutic potential.